Cite
HARVARD Citation
Strober, B. et al. (2020). Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. Journal of the European Academy of Dermatology and Venereology. pp. 2830-2838. [Online].